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Introduction
Platinum complexes are widely used in 
the treatment of many cancer entities, among 
them non-small cell lung cancer (NSCLC). 
The treatment outcome is often limited by 
the development of resistance due to mul-
tiple mechanisms [1, 2]. Previous results 
from our group have revealed that paren-
tal NSCLC cell lines are more sensitive to 
cisplatin-induced G2/M cell cycle arrest and 
apoptosis than the respective cisplatin-re-
sistant sub-line, even at cisplatin concentra-
tions that induce comparable platinum-DNA 
adduct in the different models. This suggests 
that changes in cell signaling pathways in-
volved in the regulation of the cell cycle and 
apoptosis play a role in the development of 
acquired resistance to cisplatin [Engel et al., 
manuscript in preparation].
Here, we performed a transcriptomics 
pathway analysis (microarray measurement 
of mRNA abundance) comparing the re-
sponse of the A549 NSCLC cell line and its 
cisplatin-resistant sub-line A549rCDDP2000 
to cisplatin exposure. Moreover, a literature-
based list of genes of interest (GOI), which 
may be related to cisplatin sensitivity, was 
compiled. The microarray results and the 
GOI list were then merged to identify candi-
dates for future investigations.
Material and methods
Cell culture
The human non-small cell lung carci-
noma (NSCLC) cell line A549 was obtained 
from ATCC (Manassas, VA, USA) and its cis-
platin resistant sub-line A549rCDDP2000 was 
derived from the Resistant Cancer Cell Line 
(RCCL) collection (www.kent.ac.uk/stms/
cmp/RCCL/RCCLabout.html). The sub-line 
had been established by adapting A549 cells 
to grow in the presence of increasing concen-
WUDWLRQVRIFLVSODWLQZLWKD¿QDOFRQFHQWUDWLRQ
of 2,000 ng/mL cisplatin as described previ-
ously [3]. A549 cells were grown in IMDM 
medium (PAN-Biotech, Aidenbach, Germa-
ny) containing 4 mM L-glutamine, supple-
mented with 10% fetal calf serum, 100 IU/
mL penicillin and 0.1 mg/mL streptomycin. 
The medium of the A549rCDDP2000 cells ad-
ditionally contained 2 µg/mL cisplatin. Cells 
were cultivated as monolayers in a humidi-
¿HGDWPRVSKHUH DW  &DQG&22. For 
all experiments, cells were allowed to attach 
overnight, experienced 4 hours of serum star-
vation and were subsequently treated with cis-
platin for 24 hours in IMDM medium without 
any supplement. The cells were treated with 
the respective EC10 of cisplatin, i.e. 11 µM 
for the parental and 34 µM cisplatin for the 
resistant cell line. In the following, equimolar 
treatment refers to treatment of both cell lines 
with 11 µM cisplatin and equitoxic treatment 
refers to treatment of the sensitive cell line 
with 11 µM and the resistant cell line with 
34 µM cisplatin.
Microarray
Total RNA was isolated using the my-
Budget RNA Mini Kit (Bio-Budget, Krefeld, 
Germany) according to the manufacturers 
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instruction. Isolated RNA was stored at 
±&XQWLOWKHDQDO\VLVZDVSHUIRUPHG
The transcriptome was then analyzed 
using the One-Color Whole Genome Array 
SurePrint G3 Human GE V2 8×60K Kit (Ag-
ilent Technologies, Santa Clara, CA, USA) 
according to the manufacturers instruction. 
%ULHÀ\WRWDO51$ZDVWUDQVFULEHGWRF'1$
XVLQJ $I¿QLW\6FULSW57 ROLJR G7SURPRWHU
SULPHUDQG751$SRO\PHUDVHDQGODEHOOHG
using the one-color RNA spike-in kit (positive 
controls) including cyanin 3-CTP (Cy3) dye. 
$IWHU SXULI\LQJ WKH ODEHOHGDPSOL¿HG F51$
using the RNeasy® Mini Kit (Agilent Tech-
QRORJLHVF51$ZDVTXDQWL¿HGVSHFWURSKR-
tometrically using NanoDropTM ND-1000 
7KHUPR )LVKHU 6FLHQWL¿F ,QF :DOWKDP
MA, USA). 40 µL of equivalent amounts of 
Cy3-labeled cRNA in 10× blocking agent 
and 25× fragmentation buffer, diluted with 
2× GEx HI-RPM hybridization buffer were 
loaded on the gaskets of the microarray slide 
DQGNHSWDW&IRUKRXUVZLWKUSP
of agitation. After washing twice with differ-
ent washing buffers, the microarray was read 
out with the SureScan Microarray Scanner 
System (Agilent Technologies) to obtain im-
PXQRÀXRUHVFHQFH LQWHQVLW\ 5DZ GDWD ZHUH
analyzed by the Feature Extraction software 
(Agilent Technologies). The analysis of the 
obtained microarray data was performed 




After checking the internal quality con-
trols of the microarray and quantile nor-
malization, differentially expressed genes 
'(* ZHUH LGHQWL¿HG ZLWK D IROG FKDQJH
cutoff at 2.0 and a corrected p-value cutoff 
at 0.05 (unpaired t-test, false discovery rate) 
for the three treatment conditions: A549 un-
treated vs. A549 11 µM; A549rCDDP2000 vs. 
A549rCDDP2000 11 µM and A549rCDDP2000 
untreated vs. A549rCDDP2000 34 µM cis-
platin. The DEG lists for each of the three 
treatment conditions were analyzed in a 
pathway analysis with a hypergeometric 
method (GeneSpring GX Vers. 12.6, Agilent 
Technologies) based on the WikiPathways 
database to identify pathways that were dif-
ferentially regulated by cisplatin treatment 
in the two cell lines. Pathways were catego-
rized as differentially regulated by p-values 
8VXDOO\SYDOXHVDUHXVHGIRU
that kind of analysis. In our case we decided 
to apply the more stringent cutoff because no 
correction for multiple testing was included 
in the calculation algorithm of the pathway 
DQDO\VLV7KHLGHQWL¿HGSDWKZD\VZHUHWKHQ
used to compile a genes of interest (GOI) list 
as described in the following section.
Compilation of the genes of 
interest (GOI) list
Pathways including genes that encode gene 
products that were previously reported to be in-
volved in the cellular response to cisplatin [4, 
@ZHUHVHOHFWHGIURPWKHOLVWRISDWKZD\V
Subsequently, genes belonging to these path-
ways were compiled in a list of 1,036 GOI.
,GHQWL¿FDWLRQRIFDQGLGDWHV
The genes of the GOI list were then used 
to identify a set of candidates for the biologi-
cal validation of the microarrays. Therefore, a 
Venn diagram was created to identify genes, 
regulated upon different treatment conditions 
as indicated by the microarray and overlap-
ping with the GOI list (Figure 1). Numbers in 
WKHGLIIHUHQW¿HOGVRIWKHGLDJUDPLQGLFDWHWKH
number of genes simultaneously up- or down-
regulated under the two indicated conditions. 
The gene lists were created with genes simul-
WDQHRXVO\UHJXODWHGZLWKDIROGFKDQJHDQG
DSYDOXHFXWRIILQDQXQSDLUHGWWHVWRI
Three sections of the Venn diagram were 
analyzed in detail. The central section rep-
resents genes of interest regulated under all 
treatment conditions. This section consists of 
the two genes: mouse double minute 2 ho-
mologue (MDM2), a proto-oncogene target-
ing tumor suppressor p53, and cyclin-depen-
dent kinase inhibitor 1A (CDKN1A, p21), a 
regulator of cell cycle, both p53 target genes 
involved in apoptosis regulation. Both are 
simultaneously regulated in sensitive and 
resistant cells. This suggests that there is a 
direct consequence of cisplatin treatment in-
dependently of the cellular resistance status.
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The second section is the overlap of the 
GOI genes with the genes found differen-
tially expressed between untreated and 
11 µM cisplatin-treated A549rCDDP2000 
cells. SLC12A3, a Na+/Cl symporter, is 
the only gene in this overlap. As this gene 
regulation only occurs in resistant cells af-
ter low-dose cisplatin treatment in contrast 
to the sensitive cells, SLC12A3 may be in-
volved in the mechanism of cellular toler-
ance to cisplatin.
Moreover, an overlap of 43 genes was 
found for the comparison of the GOI list with 
the genes that were differentially regulated 
in A549rCDDP2000 cells upon treatment with 
34 µM cisplatin: APAF1, BCL2, BCL2A1, 
%,. %,5& &$63 &$9Į &$9ȕ
CDKN2D, CXCL1, CXCL1 isoforms, 
'863 '863 (*) (5%% )26/
GSN, HBEGF, HRAS, IGF2, IGFBP3, IL8, 
MAP2K3, MAP3K12, MCM6, MCM9, 
MEF2C, NFE2L2, NFKB2, NRG1, NRG1 
isoforms, PLAT, PMAIP1, PRKCD, PTPRU, 
RASGRP1, RPS6KA1, RPS6KA3, RP-
S6KA5, SPRY2, TNFRSF10A, TRAF1, 
WNT4. Since these genes were not found 
differentially regulated in response to 11 µM 
cisplatin, their differential expression may 
contribute to the cisplatin resistance pheno-
type, and these genes represent candidates 
for future studies. Notably, several of these 
genes are involved in cell growth and prolif-
eration, like EGF, ERBB3, HRas or several 
mitogen-activated kinases, or play a role in 




genes whose gene products may modulate 
cell sensitivity to cisplatin and that warrant 
further investigation in subsequent studies. 
Although our method has its limitation due 
to the focus on already published data in the 
selection of pathways and genes, it provides 
a possibility to reduce the massive amount 
of data derived from a whole genome array. 
So far unknown (till now not published) af-
fected pathways, which could additionally 
account for chemoresistance were thus ex-




7KHUH DUH QR FRQÀLFWV RI LQWHUHVW WR GH-
clare.
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Figure 1. Venn diagram showing the number of simultaneously up- and down-regulated genes under 
different treatment conditions and overlap with the genes of interest (GOI) list.
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